Comment on hyperprolactinaemia and antipsychotic therapy in schizophrenia

Current Medical Research and Opinion

Volumn 20, Issue 10, 2004, Pages 1649-

  Howes, Oliver D ^a   Smith, Shubulade ^b   Aitchison, Kathy J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; RISPERIDONE;

DRUG EFFECT; DRUG MECHANISM; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; LETTER; OSTEOPENIA; OSTEOPOROSIS; PROLACTIN BLOOD LEVEL; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION;

ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; HYPERPROLACTINEMIA; OSTEOPOROSIS; PATIENT CARE PLANNING; PROLACTIN; SCHIZOPHRENIA; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 7644242523     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X4941     Document Type: Letter

References (12)

1. Hummer M, Huber J. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin 2004;20(2):189-97
2. Smith S, Wheeler MJ, Murray R, O'Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 2002;22:109-14
3. Meaney AM, Smith S, Howes OD, O'Brien M et al. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004;184:503-8
4. Smith SM, O'Keane V, Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry 2002;181:49-55
5. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-8
6. Wallace M. Real progress - the patient's perspective. Int Clin Psychopharmacol 2001;16(Suppl 1):S21-S4
7. Howes O, Smith S. Hyperprolactinaemia caused by antipsychotic drugs. Endocrine antipsychotic side effects must be systemically assessed. BMJ 2002;324:1278
8. Atmaca M, Kuloglu M, Tezcan E et al. Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol. Arch Med Res 2002;33:562-5
9. Crawford AM, Beasley CM Jr, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997;26:41-54
10. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004;44:179-87
11. Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-90
12. Casey DE, Carson WH, Saha AR et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003;166:391-9